SE0301917D0 - Methods for identifying active compounds - Google Patents

Methods for identifying active compounds

Info

Publication number
SE0301917D0
SE0301917D0 SE0301917A SE0301917A SE0301917D0 SE 0301917 D0 SE0301917 D0 SE 0301917D0 SE 0301917 A SE0301917 A SE 0301917A SE 0301917 A SE0301917 A SE 0301917A SE 0301917 D0 SE0301917 D0 SE 0301917D0
Authority
SE
Sweden
Prior art keywords
methods
active compounds
identifying active
dysregulation
agents
Prior art date
Application number
SE0301917A
Other languages
English (en)
Inventor
Vendela Parrow
Lotta Moreus
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0301917A priority Critical patent/SE0301917D0/sv
Publication of SE0301917D0 publication Critical patent/SE0301917D0/sv
Priority to PCT/SE2004/001039 priority patent/WO2005001478A1/en
Priority to US10/878,773 priority patent/US7285392B2/en
Priority to JP2006518583A priority patent/JP2007527513A/ja
Priority to EP04749077A priority patent/EP1639371A1/en
Priority to CA002528281A priority patent/CA2528281A1/en
Priority to AU2004252395A priority patent/AU2004252395A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SE0301917A 2003-06-30 2003-06-30 Methods for identifying active compounds SE0301917D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0301917A SE0301917D0 (sv) 2003-06-30 2003-06-30 Methods for identifying active compounds
PCT/SE2004/001039 WO2005001478A1 (en) 2003-06-30 2004-06-28 Methods for identifying agents, which regulate cytokines
US10/878,773 US7285392B2 (en) 2003-06-30 2004-06-28 Methods for identifying active compounds
JP2006518583A JP2007527513A (ja) 2003-06-30 2004-06-28 サイトカインを調節する作用物質の同定方法
EP04749077A EP1639371A1 (en) 2003-06-30 2004-06-28 Methods for identifying agents, which regulate cytokines
CA002528281A CA2528281A1 (en) 2003-06-30 2004-06-28 Methods for identifying agents, which regulate cytokines
AU2004252395A AU2004252395A1 (en) 2003-06-30 2004-06-28 Methods for identifying agents, which regulate cytokines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301917A SE0301917D0 (sv) 2003-06-30 2003-06-30 Methods for identifying active compounds

Publications (1)

Publication Number Publication Date
SE0301917D0 true SE0301917D0 (sv) 2003-06-30

Family

ID=27656648

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301917A SE0301917D0 (sv) 2003-06-30 2003-06-30 Methods for identifying active compounds

Country Status (2)

Country Link
US (1) US7285392B2 (sv)
SE (1) SE0301917D0 (sv)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701010D0 (sv) 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
WO2000052153A2 (en) 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors
AUPQ005399A0 (en) 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
GB0124315D0 (en) 2001-10-10 2001-11-28 Oxagen Ltd Inflammatory bowel disease

Also Published As

Publication number Publication date
US20050042691A1 (en) 2005-02-24
US7285392B2 (en) 2007-10-23

Similar Documents

Publication Publication Date Title
PL379983A1 (pl) Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE446094T1 (de) Mitotische kinesin-hemmer
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
DE602006020982D1 (de) Zusammensetzungen und verfahren zur behandlung fibrotischer störungen
NO20061194L (no) Mitotiske kinesininbibitorer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
EA200401345A1 (ru) Лечение гастропареза
DE602004011394D1 (en) Thiazolderivate
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
TW200616621A (en) Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
MXPA05009014A (es) Antagonistas del receptor ccr-3.
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
GB0326633D0 (en) Therapeutic agents
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
SE0301917D0 (sv) Methods for identifying active compounds